Title: Nispex inhibits myeloid leukemia cell HL-60 growth in vitro and in mice
Abstract: Background and purpose:Many plant-derived polyphenols have been studied for their anticancer effects and potential chemopreventive properties. Recent researches have suggested that plant polyphenols might be used to sensitize tumor cells to chemotherapeutic agents and radiation therapy by inhibiting pathways that lead to treatment resistance. These plant polyphenols have also been found to protect normal cells from therapy-associated toxicities. Nispex is an extract of Scurrula parasitica L parasitizing on Nernium indicum Mill., consisting mainly of polyphenol such as quercetin, quercitroside, avicularin and oleandrin et al. The purpose of this study was to examine the anticancer activity of Nispex in vitro and in mice, and the synergistic anticancer effect of Nispex combined with adriamycin in mice.Methods:MTT assay was used to detect the growth inhibition of human acute myeloid leukemia cells HL-60 by Nispex treatment. Xenograft of HL-60 was established by subcutaneous implantation of cultured HL-60 cells in BALB/c nude mice. Tumor growth inhibition in these mice was used to evaluate the anticancer activity of drugs. Mice used in these experiments were randomly divided into six groups: control group, ADR group, 30 mg/(kg·day)Nispex(-ip) group, 10 mg/(kg·day) Nispex-ip group,10 mg/(kg·day) Nispex-it group, 10 mg/kg per day Nispex-ip combined with ADR group. ADR were administered through caudal vein once only on the first day; Nispex treatment, 14 days. Tumor growth inhibition was evaluated by relative tumor volume (RTV) and tumor weight (TW).Results:Nispex inhibited HL-60 cells proliferation significantly in time and dose dependent manner; IC50 values were 0.75,0.70,0.54 and 0.48 μg/ml after being treated at 24, 48, 72 and 96 hr by Nispex. HL-60 grafts of 30 mg/kg per day Nospex(ip) were inhibited by 60.6% according to RTV, 31.2% according to TW(P0.05); grafts of 10mg/kg per day Nospex(it) were inhibited by 59.4% according to RTV, 45.3% according to TW(P0.05); and grafts of ADR were inhibited by 65.2% according RTV, 60.4% according to TW; grafts of 10 mg/kg per day Nospex-ip combined with ADR were inhibited by 94.4% according to RTV, 92.9% according to TW(P0.01), the coefficient of drug interaction (CDI) was 0.240.7, meaning the synergistic effect was very significant.Conclusions:Our results indicate that Nispex can inhibit human tumor growth in invro and in mice; also, it can enhance the anticancer activity of adriamycin significantly. These dates suggest that Nispex may be useful in cancer chemotherapy.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot